Entradas destacadas

Hemoglobina Glicosilada por Cobas Integra 800 unica en el mercado aprobada por FDA

May 13, 2016

FDA allows marketing of first A1c test labeled for diagnosing diabetes

 

Today the U.S. Food and Drug Administration announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabetes by health care professionals. This is the first HbA1c test that FDA has allowed to be marketed for this use.

The HbA1c tests, or A1c tests, currently on the market are FDA-cleared for monitoring a patient’s blood glucose (sugar) control, but not for diagnosing diabetes. A1c tests measure the percentage of hemoglobin A1c that is bound to glucose, giving a patient’s average glucose level over a three-month period. 

Diabetes is a serious, chronic metabolic condition where the body is unable to convert glucose into the energy needed to carry out daily activities. An estimated 25.8 million people in the United States have diabetes, including seven million people who remain undiagnosed. If left untreated, high blood glucose levels (hyperglycemia) can lead to serious long-term problems such as stroke, heart disease, and damage to the eyes, kidneys, and nerves.

 

Leer Mas...

Please reload

Exigen renuncia a comisionada de seguros

May 13, 2016

1/1
Please reload

Entradas recientes
Please reload

Archivo
Please reload

Buscar por tags
Please reload